Livanova News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.12.24	RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression (Businesswire)
05.12.24	LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting (Businesswire)
14.11.24	LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences (Businesswire)
11.11.24	LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints (Businesswire)
08.10.24	LivaNova Appoints Susan Podlogar as a New Director (Businesswire)
25.09.24	LivaNova to Announce Third-Quarter 2024 Results (Businesswire)
19.08.24	LivaNova to Present at the Baird Global Healthcare Conference (Businesswire)
18.06.24	LivaNova to Announce Second-Quarter 2024 Results (Businesswire)
06.06.24	LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients (Businesswire)
23.05.24	LivaNova to Present at the Goldman Sachs Healthcare Conference (Businesswire)
30.04.24	LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer (Businesswire)
25.04.24	LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident (Businesswire)
21.03.24	LivaNova to Announce First-Quarter 2024 Results (Businesswire)
20.03.24	LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea (Businesswire)
06.03.24	LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029 (Businesswire)
04.03.24	LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes (Businesswire)
04.03.24	LivaNova to Present at the Barclays Global Healthcare Conference (Businesswire)
05.02.24	LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director (Businesswire)
08.01.24	LivaNova to Wind Down Advanced Circulatory Support Business Unit (Businesswire)
04.01.24	LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results (Businesswire)
09.11.23	LivaNova to Present at the Piper Sandler Healthcare Conference (Businesswire)
25.10.23	LivaNova to Present at the Stifel and Wolfe Healthcare Conferences (Businesswire)
21.09.23	LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023 (Businesswire)
20.09.23	LivaNova to Announce Third-Quarter 2023 Results (Businesswire)
31.08.23	LivaNova präsentiert Essenz In-Line Blood Monitor mit U.S. FDA 510(k)-Zulassung und CE-Prüfzeichen (Businesswire)
30.08.23	LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark (Businesswire)
24.08.23	LivaNova to Present at the Baird Global Healthcare Conference (Businesswire)
14.06.23	LivaNova to Announce Second-Quarter 2023 Results (Businesswire)
13.06.23	LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study (Businesswire)
14.04.23	LivaNova Board of Directors Announce Leadership Changes (Businesswire)
22.03.23	LivaNova to Announce First-Quarter 2023 Results (Businesswire)
10.03.23	LivaNova erhält 510(k)-Freigabe der US-amerikanischen FDA für Essenz-Herz-Lungen-Maschine für kardiopulmonale Bypassverfahren (Businesswire)
09.03.23	LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures (Businesswire)
09.03.23	LivaNova to Present at the Barclays Global Healthcare Conference (Businesswire)
08.02.23	LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures (Businesswire)
02.02.23	LivaNova Launches SenTiva DUO (Businesswire)
18.01.23	LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results (Businesswire)
13.12.22	LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration (Businesswire)
30.11.22	LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting (Businesswire)
17.11.22	LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System (Businesswire)
08.11.22	LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences (Businesswire)
21.09.22	LivaNova to Announce Third-Quarter 2022 Results (Businesswire)
15.09.22	LivaNova Board Appoints Brooke Story as a New Director (Businesswire)
22.06.22	LivaNova to Announce Second-Quarter 2022 Results (Businesswire)
14.06.22	LivaNova Elects Peter Wilver to Board of Directors (Businesswire)
25.05.22	LivaNova to Present at the Goldman Sachs Global Healthcare Conference (Businesswire)
08.04.22	LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures (Businesswire)
24.03.22	LivaNova to Announce First-Quarter 2022 Results (Businesswire)
14.03.22	LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study (Businesswire)
24.02.22	LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Livanova PLC

Aktien Top/Flop

Livanova Peer Group Nachrichten

Meistgelesene Nachrichten